Drug recall · August 9, 2023
Tydemy (drospirenone recall
Why: Failed Stability Specification and Failed Impurities/Degradation Specifications: out of specification for inactive content ascorbic acid and MTHFRC-7impurity test
Class I: a reasonable chance the product could cause serious harm or death.
The recall
- Product
Tydemy (drospirenone, ethinyl estradiol and levomefolate calcium tablets, 3 mg/0.03 mg/0.451 mg and levomefolate calcium tablets 0.451 mg), packaged in 1 blister of 28 tablets each (NDC 68180-904-71) further packaged in a carton of 3 blisters (NDC 68180-904-73), Distributed by: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, Manufactured by Lupin Limited, Pithampur (M.P.), INDIA
- Lots / codes
Lot #: L200183, Exp 1/2024; L201560, Exp 9/2024
- Quantity
- 4,179 boxes/_ cartons per box/3 pouches each/28 blister per pouch
- Company
- Lupin Pharmaceuticals Inc., Baltimore, MD
- Distribution
- USA nationwide.
- Initiated
- June 23, 2023 · Voluntary: Firm initiated
- Classified
- August 4, 2023
- Reported
- August 9, 2023
- Ended
- January 28, 2025
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Drospirenone / ethinyl estradiol / levomefolate
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.